{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:59:21Z","timestamp":1782993561556,"version":"3.54.5"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ajconline.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.amjcard.2017.06.062","type":"journal-article","created":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T00:32:24Z","timestamp":1500078744000},"page":"1166-1170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction"],"prefix":"10.1016","volume":"120","author":[{"given":"Wilbert S.","family":"Aronow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3584-2008","authenticated-orcid":false,"given":"Tatyana A.","family":"Shamliyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2017.06.062_bib0010","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0015","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0020","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/heartjnl-2014-306775","article-title":"The neprilysin pathway in heart failure: a review and guide on the use of sacubitril\/valsartan","volume":"102","author":"Jhund","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0025","doi-asserted-by":"crossref","first-page":"e002551","DOI":"10.1161\/CIRCHEARTFAILURE.115.002551","article-title":"Plasma biomarkers reflecting profibrotic processes in heart failure with a preserved ejection fraction: data from the prospective comparison of ARNI with ARB on management of heart failure with preserved ejection fraction study","volume":"9","author":"Zile","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0030","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1161\/CIRCHEARTFAILURE.114.001427","article-title":"Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696","volume":"7","author":"Jhund","year":"2014","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0035","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0040","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.amjmed.2017.02.010","article-title":"Sacubitril\/Valsartan: the newest addition to the toolbox for guideline directed medical therapy of heart failure","volume":"130","author":"Rodgers","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0050","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"Ponikowski","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0055","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.cardfail.2016.07.001","volume":"22","author":"Writing Committee Members","year":"2016","journal-title":"J Card Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0065","doi-asserted-by":"crossref","first-page":"e002560","DOI":"10.1161\/CIRCHEARTFAILURE.115.002560","article-title":"Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial","volume":"9","author":"Kristensen","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ijcard.2014.11.059","article-title":"Neprilysin inhibitors preserve renal function in heart failure","volume":"179","author":"Bodey","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0075","doi-asserted-by":"crossref","first-page":"e002744","DOI":"10.1161\/CIRCHEARTFAILURE.115.002744","volume":"9","author":"Solomon","year":"2016","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0080","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of clinical worsening of heart failure treated in the outpatient setting: evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0085","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","article-title":"Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF","volume":"36","author":"Jhund","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0090","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1093\/eurheartj\/ehv186","article-title":"Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients","volume":"36","author":"Desai","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0095","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/j.jacc.2015.08.878","article-title":"Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF","volume":"66","author":"Simpson","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0100","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0110","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0115","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.tcm.2017.01.003","article-title":"Heart failure guidelines: what's new?","volume":"27","author":"Papadimitriou","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0120","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1160\/TH12-08-0578","article-title":"Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis","volume":"108","author":"Lip","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0125","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","article-title":"Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"King","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0130","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0135","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0140","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0145","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0150","author":"Novartis Pharmaceuticals"},{"key":"10.1016\/j.amjcard.2017.06.062_bib0155","author":"Novartis Pharmaceuticals"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917311244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914917311244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T02:30:10Z","timestamp":1535596210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914917311244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0002914917311244"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.062","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefits and Harms of Sacubitril in Adults With Heart Failure and Reduced Left Ventricular Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2017.06.062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}